Service de diabétologie, maladies métaboliques et nutrition, pôle cardiovasculaire et métabolique, CHU Rangueil, Toulouse, France.
Ann Endocrinol (Paris). 2013 Jul;74(3):207-10. doi: 10.1016/j.ando.2013.04.001. Epub 2013 Jun 6.
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement in 2012 on the management of hyperglycaemia in patients with type 2 diabetes. The Société Francophone du Diabète (SFD) adopted it while awaiting future French recommendations. This new care approach individualises the therapeutic choices and objectives for each patient based on their characteristics, through emphasis on the need for mutual cooperation with the patient in decision-making. Glycaemic management should naturally be considered in the context of overall cardiovascular risk reduction, which should remain the primary objective of treatment. The cornerstone of this treatment is based on lifestyle modifications, with the addition of metformin monotherapy if the desired glycaemic control is not attained. There are multiple second- and third-line treatment possibilities, and insulin therapy is an option that can be considered early in the bitherapy stage. On the whole, large published studies at the ADA conference in Philadelphia in June 2012, which are the subject of this article, support this patient-centred position statement.
2012 年，美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）发布了一份关于 2 型糖尿病患者高血糖管理的立场声明。法国糖尿病学会（SFD）在等待未来的法国建议的同时通过了该声明。这种新的护理方法根据患者的特点，将治疗选择和目标个体化，强调需要与患者共同决策。血糖管理应自然考虑到整体心血管风险降低的情况，这仍然是治疗的主要目标。这种治疗的基石是基于生活方式的改变，如果未能达到预期的血糖控制，可以添加二甲双胍单药治疗。还有多种二线和三线治疗的可能性，胰岛素治疗是一种可以在双联治疗早期考虑的治疗方法。总的来说，2012 年 6 月在费城举行的 ADA 会议上发表的大量已公布的研究支持了这一以患者为中心的立场声明。
